Lunaphore and CRO Sirona Dx Collaborate to Expand COMET™ Offerings to US-based Biotech and Biopharma Customers
Lunaphore, a Swiss life sciences company developing technology to enable spatial biology in every laboratory, and Sirona Dx, a leader in multi-omics, single-cell analytical services, today announced a strategic collaboration in which Sirona Dx will become the first US-based Contract Research Organization (CRO) to offer Lunaphore’s flagship COMET™ spatial biology platform as a service. COMET™ will complement Sirona Dx’s portfolio of research service offerings to meet the needs of researchers and biopharma teams across various disciplines.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230223005618/en/
Lunaphore’s COMET™ platform is the only fully automated, high-throughput, hyperplex platform with superior tissue profiling capabilities. Its capacity allows the generation of high-quality and reproducible data on large cohorts of samples in days. In contrast to other spatial biology solutions, COMET™ works with off-the-shelf, label-free primary antibodies, enabling customers to use their trusted antibodies and making panel design fast and flexible. Thanks to its versatility, COMET™ has a wide range of research applications across multiple disciplines and all stages of research and drug development.
Sirona Dx is a highly-specialized technical CRO and pioneer of single-cell and spatial biology, having launched ultra-high parameter, multiplexed single-cell services to biopharma in 2018. Their innovative, technology-agnostic service capabilities contributed to their selection as a Top 10 CRO of 2021 by Medhealth Outlook.
“Platform selection is one of the most important decisions to make when developing multiplexed tissue imaging panels for our clients”, said Andrew Brown, Ph.D., Chief Commercial Officer at Sirona Dx. “We are extremely pleased to partner with Lunaphore to integrate the COMET™ platform into our spatial-omics operations. The ability to select off-the-shelf, label-free primary antibodies is highly advantageous and reduces the time required to develop robust, highly reproducible assays.
“The deployment of COMET™ at Sirona Dx is particularly meaningful for Lunaphore as it helps to address the large demand from US-based biotech and biopharmaceutical companies to access highly reproducible hyperplex data,” said Déborah Heintze, Chief Marketing Officer at Lunaphore. “Furthermore, Sirona Dx’s CLIA certification and deep understanding of pharmaceutical regulatory requirements add significant value for scientists looking to adopt spatial biology tools to accelerate translational research”.
To learn more about the COMET™ platform, please visit:
https://lunaphore.com/products/comet/
To learn more about Lunaphore, please visit: https://lunaphore.com/
About Lunaphore
Lunaphore Technologies S.A. is a Swiss company born in 2014 with the vision of enabling spatial biology in every laboratory. Lunaphore provides solutions based on a game-changing chip technology that can extract spatial proteomic and transcriptomic data from tumors and other tissues, transforming any assay into multiplex spatial biology with an intuitive approach. Lunaphore empowers researchers in immunology, immuno-oncology, and neuroscience to push the boundaries of scientific discovery and drug development. Lunaphore’s technology enables the identification of biomarker “signatures” with clinical relevance to support the development of diagnostic tools and streamline clinical trials, to ultimately improve patient outcomes. For further information on Lunaphore and its products, please visit: www.lunaphore.com
About COMET™
COMET™ is a fully automated, sequential immunofluorescence (seqIF™) instrument, able to perform hyperplex staining and imaging, producing high-quality data in a robust and reproducible manner. With superior tissue profiling capabilities, the system allows multiplex analysis of 40 different spatial markers per automated run on a tissue slide. COMET™ has a wide range of research applications, allowing for a dramatic improvement in the understanding of disease pathology in areas such as immuno-oncology, neuroscience, and infectious diseases. To learn more about the COMET™ platform, please visit: https://lunaphore.com/products/comet/
About Sirona Dx
Sirona Dx is a technical CRO, founded in 2016 to accelerate the pace of immunotherapy and targeted therapy development. Bridging silos between diagnostics manufacturers and translational clinical research, Sirona Dx offers specialized high complexity, single-cell services supporting exploratory biomarker programs and advanced precision medicine initiatives to deliver safer and more effective treatment solutions. Learn more at Sironadx.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230223005618/en/
Contact information
For further information contact:
Irene Tamayo
Lunaphore Corporate Communications
Email: communications@lunaphore.com
Andrew Brown, PhD
Chief Commercial Officer, Sirona Dx
Email: abrown@sironadx.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Quectel Announces Industry First 5G-Advanced 3GPP R18 Automotive-Grade Cellular Module, Delivering Unmatched Performance and Reliability2.1.2026 19:00:00 EET | Press release
Quectel Wireless Solutions, an end-to-end global IoT solutions provider, today announces the launch of the world's first 5G-advanced (5G-A) automotive-grade cellular module, the AR588MA, establishing it as the industry's highest-performing and most reliable wireless communication product for vehicles. Based on MediaTek's latest-generation MT2739 platform, the AR588MA supports 5G-A communication technology and is the world's first to comply with the 3GPP R18 standard protocol. The module also features both NB-NTN and NR-NTN satellite communication capabilities, supports Dual SIM Dual Active (DSDA) technology, offering improved stability and reliability on cellular connections and includes intelligent driving scenario recognition. Designed in compliance with the AEC-Q104 Grade 2 automotive standard, it delivers faster, more stable connectivity and reliable security for in-vehicle communication and benefiting the on-roof applications like smart antenna for automotive with higher temperatu
Interactive Brokers’ Individual and Hedge Fund Clients Outperformed the S&P 500 on Average in 20252.1.2026 17:00:00 EET | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global electronic broker, today announced that its clients outperformed the S&P 500 Index in 2025, reflecting the benefits of cost efficiency, execution quality, and broad access to global markets. In 2025, Interactive Brokers’ individual clients achieved an average return of 19.20%, compared with the 17.9% return of the S&P 500 Index. During the same period, Interactive Brokers’ hedge fund clients achieved an average return of 28.91%, outperforming the index by approximately 11 percentage points. These results demonstrate how Interactive Brokers helps enhance client returns across the investment lifecycle. Global market access enables clients to allocate capital across various regions and asset classes, while lower trading and financing costs, along with efficient execution, help IBKR investors retain more of their returns over time. “Investment returns are not just about picking the right trades. They are influenced by the costs you pa
Aeromexico Repeats as Most On-Time Global Airline; Qatar Airways Claims Platinum Award2.1.2026 12:00:00 EET | Press release
Aeromexico maintained a 90.02% on-time performance to claim the world's most on-time global airline title for the second consecutive year, according to Cirium's 2025 On-Time Performance Review released today. The Mexican carrier becomes only the second airline to achieve consecutive global wins since Cirium launched the program in 2009, operating 188,859 flights across 23 countries while maintaining industry-leading schedule reliability. Aeromexico Holds Global Lead; Regional Champions Crowned Aeromexico secured the global airline title with 90.02% on-time performance, holding off strong competition from Saudia in second place with 86.53% and SAS with 86.09% in third. The margin between first and third place was 3.93 percentage points, reflecting the strong performance of Aeromexico in 2025. Regional winners included: North America: Delta Air Lines won for the fifth consecutive year with 80.90% on-time performance Europe: Iberia Express (International Airlines Group) defended its title
Samsung Bioepis Begins Commercialization of BYOOVIZ ® , Biosimilar to Lucentis (Ranibizumab), in Europe2.1.2026 09:00:00 EET | Press release
Samsung Bioepis Co., Ltd. today announced that the company has begun direct commercialization of BYOOVIZ®, a biosimilar to Lucentis1 (ranibizumab), in Europe. Samsung Bioepis has been working to ensure seamless transfer of commercial rights from Biogen back to Samsung Bioepis, and BYOOVIZ will now be available as a Samsung Bioepis brand across multiple European countries. “This is a significant milestone for Samsung Bioepis as the company continues to strengthen its presence in Europe by expanding its portfolio of directly commercialized products. Leveraging the past three years of experience with EPYSQLI (eculizumab) and the newly launched OBODENCE (denosumab) and XBRYK (denosumab) in Europe, we will continue on our journey to become a fully integrated biopharmaceutical company with end-to-end capabilities from development to commercialization,” said Antonio Rito, Vice President and Head of Europe, at Samsung Bioepis. “We will work closely with payers and healthcare professionals to e
Cessna Citation Ascend Enters Into Service, Redefining Performance and Cabin Experience in the Midsize Business Jet Market31.12.2025 16:00:00 EET | Press release
The Cessna Citation Ascend achieved a major milestone as the first retail customer took delivery of the midsize business jet on Tuesday, December 30, marking the aircraft’s entry into service. Announced in 2023 the aircraft boasts an entirely new cockpit, improved performance and a luxurious flat floor cabin. The Citation Ascend received type certification from the Federal Aviation Administration (FAA) in November 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251231586042/en/ Cessna Citation Ascend enters into service, redefining performance and cabin experience in the midsize business jet market. (Photo credit: Textron Aviation) The Cessna Citation Ascend is designed and manufactured by Textron Aviation Inc., a Textron Inc. (NYSE: TXT) company. “The first Citation Ascend delivery underscores Textron Aviation’s commitment to redefining the midsize segment with an aircraft that blends innovation, efficiency and unmatch
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom